Hemcheck Sweden AB (publ) extended the agreement with Laboratory Medicine within Region Skåne, Sweden. The extension involves minor revenues for Hemcheck and is related to the same project as previously communicated where Hemcheck's v-Test with equipment configured for diagnostic use is used.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.148 SEK | +23.33% | +22.31% | -37.82% |
May. 13 | Bio Vitos Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 14 | Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-37.82% | 4.13M | |
-4.72% | 12.35B | |
+99.06% | 8.55B | |
-22.10% | 6.6B | |
+8.48% | 5.88B | |
-22.96% | 3.52B | |
+6.08% | 2.55B | |
+38.04% | 2.39B | |
-7.04% | 2.33B | |
-68.75% | 2.09B |
- Stock Market
- Equities
- BIOVIT Stock
- News Bio Vitos Pharma AB
- Hemcheck Sweden AB Extends Agreement Regarding Previously Communicated Project with Region Skåne